Intravenous gammaglobulin (IVIG): a novel approach to improve transplant rates and outcomes in highly HLA-sensitized patients.

Jordan, S C; Vo, A A; Peng, A; Toyoda, M; Tyan, D

Jordan, S C; Vo, A A; Peng, A; Toyoda, M; Tyan, D.

Affiliation

Jordan SC; Comprehensive Transplant Center, Cedars-Sinai Medical Center, UCLA School of Medicine, University of California-Los Angeles, Los Angeles, CA, USA. sjordan@cshs.org

Am J Transplant ; 6(3): 459-66, 2006 Mar.

Article in En | MEDLINE | ID: mdl-16468954

Subject(s)

Graft Rejection/drug therapy; Graft Survival/drug effects; HLA Antigens/immunology; Immunoglobulins, Intravenous/administration & dosage; Kidney Transplantation; gamma-Globulins/administration & dosage; Graft Rejection/immunology; Humans; Immunoglobulins, Intravenous/therapeutic use; Treatment Outcome; gamma-Globulins/therapeutic use

Search on Google

Add to My VHL

XML

PubMed Links

Collection: 01-internacional Database: MEDLINE Main subject: Gamma-Globulins / Kidney Transplantation / Immunoglobulins, Intravenous / Graft Rejection / Graft Survival / HLA Antigens Limits: Humans Language: En Journal: Am J Transplant Journal subject: TRANSPLANTE Year: 2006 Document type: Article Affiliation country: United States Country of publication: United States

Search on Google

Add to My VHL

XML

PubMed Links